NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: What lies beyond the horizon

Wolfe, 1999, Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, N Engl J Med, 340, 1888, 10.1056/NEJM199906173402407

FitzGerald, 2003, COX-2 and beyond: approaches to prostaglandin inhibition in human disease, Nat Rev Drug Discov, 2, 879, 10.1038/nrd1225

FitzGerald, 2001, The coxibs, selective inhibitors of cyclooxygenase-2, N Engl J Med, 345, 433, 10.1056/NEJM200108093450607

Wallace, 1996, The cellular and molecular basis of gastric mucosal defense, FASEB J, 10, 731, 10.1096/fasebj.10.7.8635690

Lazzaroni, 2007, Coxibs and non-selective NSAIDs in the gtsrointestinal setting: what should patients and physicians do, Dig Liv Dis, 39, 589, 10.1016/j.dld.2007.04.002

Silverstein, 1995, Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 123, 241, 10.7326/0003-4819-123-4-199508150-00001

Hawkey, 1998, Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group, N Engl J Med, 338, 727, 10.1056/NEJM199803123381105

Yeomans, 1998, A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group, N Engl J Med, 338, 719, 10.1056/NEJM199803123381104

Fiorucci, 2003, NO-aspirin: mechanism of action and gastrointestinal safety, Dig Liver Dis, 35, S9, 10.1016/S1590-8658(03)00047-1

Wallace, 2002, Potential cardioprotective actions of nitric oxide-releasing aspirin, Nat Rev Drug Discov, 1, 375, 10.1038/nrd794

Fiorucci, 2006, NO-NSAIDs: from inflammatory mediators to clinical readouts, Inflamm Allergy Drug Targets, 5, 121, 10.2174/187152806776383161

Wallace, 2007, Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat, Gastroenterology, 132, 261, 10.1053/j.gastro.2006.11.042

Li, 2007, Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative, Free Radic Biol Med, 42, 706, 10.1016/j.freeradbiomed.2006.12.011

Fiorucci, 2006, The emerging roles of hydrogen sulphide in the gastrointestinal tract and liver, Gastroenterology, 131, 259, 10.1053/j.gastro.2006.02.033

Fiorucci, 2002, Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage, Gastroenterology, 123, 1598, 10.1053/gast.2002.36558

Bresalier, 2005, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, 1092, 10.1056/NEJMoa050493

Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, N Engl J Med, 343, 1520, 10.1056/NEJM200011233432103

Silverstein, 2000, Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study, J Am Med Assoc, 284, 1247, 10.1001/jama.284.10.1247

Schnitzer, 2004, Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial, Lancet, 364, 665, 10.1016/S0140-6736(04)16893-1

Farkouh, 2004, Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial, Lancet, 364, 675, 10.1016/S0140-6736(04)16894-3

Nussmeier, 2005, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery, N Engl J Med, 352, 1081, 10.1056/NEJMoa050330

Johnsen, 2005, Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study, Arch Intern Med, 165, 978, 10.1001/archinte.165.9.978

Juni, 2004, Risk of cardiovascular events and rofecoxib: cumulative meta-analysis, Lancet, 364, 2021, 10.1016/S0140-6736(04)17514-4

Wallace, 2003, A magic bullet for mucosal protection … and aspirin is the trigger!, Trends Pharmacol Sci, 24, 323, 10.1016/S0165-6147(03)00166-4

Fiorucci, 2003, Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin, FASEB J, 17, 1171, 10.1096/fj.02-0777fje

Fiorucci, 2003, Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa, Proc Natl Acad Sci U S A, 100, 10937, 10.1073/pnas.1933204100

Wallace, 1990, Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process, Am J Physiol, 259, G462

Wallace, 1991, A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit, Gastroenterology, 100, 878, 10.1016/0016-5085(91)90259-N

Santucci, 1995, Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats, Gastroenterology, 108, 393, 10.1016/0016-5085(95)90065-9

Wallace, 1994, A diclofenac derivative without ulcerogenic properties, Eur J Pharmacol, 257, 249, 10.1016/0014-2999(94)90136-8

Wallace, 1994, Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat, Gastroenterology, 107, 173, 10.1016/0016-5085(94)90074-4

Stefano, 2007, Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a reviewof their current status, Curr Top Med Chem, 7, 277, 10.2174/156802607779941350

Fiorucci, 2004, J Pharmacol Exp Ther, 311, 1264, 10.1124/jpet.104.072843

Fiorucci, 1999, Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats, Gastroenterology, 116, 1089, 10.1016/S0016-5085(99)70012-0

Fiorucci, 2003, Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study, Gastroenterology, 124, 600, 10.1053/gast.2003.50096

Fiorucci, 2004, Nitric oxide regulates immune cell bioenergetic: a mechanism to understandimmunomodulatory functions of nitric oxide-releasing anti-inflammatory drugs, J Immunol, 173, 874, 10.4049/jimmunol.173.2.874

Hawkey, 2003, Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans, Gut, 52, 1537, 10.1136/gut.52.11.1537

Lohmander, 2005, STAR Multinational Study Group, Ann Rheum Dis, 64, 449, 10.1136/ard.2004.023572

Huledal, 2005, Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake, Clin Pharmacol Ther, 77, 437, 10.1016/j.clpt.2005.01.011

Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen. Drugs R D 2006; 7(4):262–6.

Schnitzer, 2005, Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee, Arthritis Rheum, 53, 827, 10.1002/art.21586

Wang, 2002, Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?, FASEB J, 16, 1792, 10.1096/fj.02-0211hyp

Distrutti, 2006, Evidence that hydrogen sulphide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels, J Pharmacol Exp Ther, 316, 325, 10.1124/jpet.105.091595

Goubern, 2007, Sulfide, the first inorganic substrate for human cells, FASEB J, 21, 1699, 10.1096/fj.06-7407com

Distrutti, 2006, 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulphide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity, J Pharmacol Exp Ther, 319, 447, 10.1124/jpet.106.106435

Zanardo, 2006, Hydrogen sulphide is an endogenous modulator of leukocyte-mediated inflammation, FASEB J, 20, 2118, 10.1096/fj.06-6270fje

Ortiz, 2001, Evidence for a new mechanism of action of diclofenac: activation of K+ channels, Proc West Pharmacol Soc, 44, 19

Fiorucci, 2007, Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis, Br J Pharmacol, 150, 996, 10.1038/sj.bjp.0707193